Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer

Sun, Jingjing; Wan, Zhuoya; Xu, Jieni; Luo, Zhangyi; Ren, Pengfei; Zhang, Bei; Diao, Dingwei; Huang, Yixian; Li, Song

doi:10.1016/j.biomaterials.2020.120629

Cited by 37 publications

(29 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the co ‐stimulation of regulating T cells could activate cancer‐specific immune responses, especially for treating mid and late‐stage tumor patients synergistically. [ 172 ]…”

Section: Exo‐stimuli‐responsive Nanoparticles (Ex‐srnps) For Smart Dr...mentioning

confidence: 99%

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Zhang

Lin

Lin³

et al. 2021

Advanced Science

154

View full text Add to dashboard Cite

Cancer immunotherapy has achieved promising clinical progress over the recent years for its potential to treat metastatic tumors and inhibit their recurrences effectively. However, low patient response rates and dose-limiting toxicity remain as major dilemmas for immunotherapy. Stimuli-responsive nanoparticles (srNPs) combined with immunotherapy offer the possibility to amplify anti-tumor immune responses, where the weak acidity, high concentration of glutathione, overexpressions of enzymes, and reactive oxygen species, and external stimuli in tumors act as triggers for controlled drug release. This review highlights the design of srNPs based on tumor microenvironment and/or external stimuli to combine with different anti-tumor drugs, especially the immunoregulatory agents, which eventually realize synergistic immunotherapy of malignant primary or metastatic tumors and acquire a long-term immune memory to prevent tumor recurrence. The authors hope that this review can provide theoretical guidance for the construction and clinical transformation of smart srNPs for controlled drug delivery in synergistic cancer immunotherapy.

show abstract

Section: Exo‐stimuli‐responsive Nanoparticles (Ex‐srnps) For Smart Dr...mentioning

confidence: 99%

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Zhang

Lin

Lin³

et al. 2021

Advanced Science

154

View full text Add to dashboard Cite

show abstract

“…91 Mature stimulated DCs showed a strong enhancement in stimulating the original autologous T helper cells and secreting cytokine numbers. 92,93 At the same time, fucoidan was a sulfurated polysaccharide purified form, which has a variety of immunomodulatory effects, including promoting antigen uptake and enhancing antiviral and anti-tumor effects. It was an excellent adjuvant to induce Th1 immune response and CTL activation, which may contribute to the development of tumor vaccines.…”

Section: Pure-phased Organic Composites As Functional Agents In Cance...mentioning

confidence: 99%

Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies

Chen

2022

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…In turn, local tryptophan depletion, combined with accumulating levels of metabolites, leads to a dampening of both innate and adaptive antitumour responses [ 240 , 241 ]. Efforts to remedy this metabolic alteration have yielded a wealth of nanoplatforms encapsulating IDO1-targeted agents, such as small molecule inhibitors or siRNA, often in combination with another immunomodulatory cargo [ 242 , 243 , 244 , 245 ]. These have proven highly effective in mobilising antitumour immunity, as demonstrated by the development of a hybrid lipid-mesoporous silica nanoformulation encapsulating the IDO1 inhibitor indoximod and the ICD-inducer oxaliplatin [ 190 ].…”

Section: Addressing Therapy Resistance In Paca Using Nanoparticle-based Platformsmentioning

confidence: 99%

Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance

Greene

Johnston

Scott

2021

Cancers

View full text Add to dashboard Cite

The development of drug resistance remains one of the greatest clinical oncology challenges that can radically dampen the prospect of achieving complete and durable tumour control. Efforts to mitigate drug resistance are therefore of utmost importance, and nanotechnology is rapidly emerging for its potential to overcome such issues. Studies have showcased the ability of nanomedicines to bypass drug efflux pumps, counteract immune suppression, serve as radioenhancers, correct metabolic disturbances and elicit numerous other effects that collectively alleviate various mechanisms of tumour resistance. Much of this progress can be attributed to the remarkable benefits that nanoparticles offer as drug delivery vehicles, such as improvements in pharmacokinetics, protection against degradation and spatiotemporally controlled release kinetics. These attributes provide scope for precision targeting of drugs to tumours that can enhance sensitivity to treatment and have formed the basis for the successful clinical translation of multiple nanoformulations to date. In this review, we focus on the longstanding reputation of pancreatic cancer as one of the most difficult-to-treat malignancies where resistance plays a dominant role in therapy failure. We outline the mechanisms that contribute to the treatment-refractory nature of these tumours, and how they may be effectively addressed by harnessing the unique capabilities of nanomedicines. Moreover, we include a brief perspective on the likely future direction of nanotechnology in pancreatic cancer, discussing how efforts to develop multidrug formulations will guide the field further towards a therapeutic solution for these highly intractable tumours.

show abstract

Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer

Cited by 37 publications

References 47 publications

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy

Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies

Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance

Contact Info

Product

Resources

About